Foghorn therapeutics announces fda has lifted clinical hold on phase 1 study of fhd-286 in relapsed and/or refractory aml/mds patients

- plan to initiate a phase 1 study of fhd-286 in combination with decitabine or cytarabine in relapsed and/or refractory aml patients in q3'2023

FHTX Ratings Summary

FHTX Quant Ranking